

Editorial

Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach[☆]

Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica

José María Lamas-Barreiro^{a,*}, Mario Alonso-Suárez^a, Jorge Julián Fernández-Martín^b,
Jesus Angel Saavedra-Alonso^a

^a Servicio de Nefrología, Complejo Hospitalario Universitario de Vigo, Vigo, Spain

^b Servicio de Medicina Interna, Complejo Hospitalario Universitario de Vigo, Vigo, Spain

The renin–angiotensin system (RAS) is a known regulator of cardiovascular function, involved in hypertension, kidney disease, heart disease, arteriosclerosis, diabetes, and lung disease.^{1,2}

It has been confirmed that the SARS-CoV-2 virus, like other coronaviruses, enters lung cells by binding to angiotensin-converting enzyme 2 (ACE2),^{3,4} which is an important element of the RAS. The main function of this enzyme, which is expressed in various human tissues,⁵ appears to be the maintenance of a balance between this vasoconstricting system, proinflammatory, proliferative, profibrotic, and oxidant effects and the other antagonizing effects through degradation and decreased production of angiotensin II and formation of angiotensin 1–7^{6–8} (Fig. 1). It seems that the main mechanism by which ACE2 regulates angiotensin II is direct degradation, as its effect on angiotensin II has been estimated to be 400 times greater than its effect on angiotensin I.⁹

In recent years, various studies have been published on ACE2's possible beneficial effects on the cardiovascular system, kidneys, and lungs,^{10–13} which have been linked to its

angiotensin II-suppressing effect. Imai et al.¹³ found that angiotensin II worsened respiratory distress in different experimental models and that this poor course improved with angiotensin II receptor type 1 (AT1) blockade. They also found that the course worsened in the event of a reduction in ACE2 expression, as in coronavirus infections, and argued that this unfavorable course was due in part to a drop in angiotensin II regulation by this enzyme.

In this same line, Gurwitz¹⁴ and other authors^{15,16} have suggested that angiotensin II receptor blockers (ARBs) could have a beneficial effect on the course of lung disease in SARS-CoV-2 infection, either directly due to their capacity to increase ACE2 levels by counteracting the decrease in levels caused by the virus, or by blocking AT1 receptors and thus impeding the action of a possible excess of angiotensin II, the harmful effects of which in the lungs have been reported in cases of pneumonia due to the SARS-CoV-2 virus¹⁵ and the avian influenza A virus.¹⁷

In an experimental study in rats, Ferrario et al.¹⁸ found conflicting data on the effects of lisinopril, an ACE inhibitor, and

DOI of original article:

<https://doi.org/10.1016/j.nefro.2020.04.006>.

[☆] Please cite this article as: Lamas-Barreiro JM, Alonso-Suarez M, Fernández-Martín JJ, Saavedra-Alonso JA. Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica. *Nefrología*. 2020;40:213–216.

* Corresponding author.

E-mail address: jose.maria.lamas.barreiro@sergas.es (J.M. Lamas-Barreiro).

2013-2514/© 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Figure 1 – Diagram of the renin–angiotensin system. ACE: angiotensin-converting enzyme; ACE2: angiotensin-converting enzyme 2; ARB: AT1 receptor blocker; AT1: angiotensin II receptor type 1; AT2: angiotensin II receptor type 2; Mas: mitochondrial assembly receptor.

losartan, an ARB, on mRNA expression of ACE2 and the activity of this enzyme, observing that both increase mRNA expression of ACE2, although only losartan, not lisinopril, increases its activity. Based on this study and on the fact that patients at higher cardiovascular risk infected with the SARS-CoV-2 virus seem to follow a worse course, Sommerstein and Gräni suggested that treatment with ACE inhibitors could have an unfavorable effect under these circumstances.¹⁹ By contrast, studies conducted in humans have not found any association between use of ACE inhibitors or ARBs and levels of ACE2.²⁰

In line with Imai et al.¹³, the worse course in infection with the SARS-CoV-2 virus in patients at higher cardiovascular risk (hypertensive, diabetic, and elderly patients as well as those with greater cardiac morbidity)²¹ could also be interpreted to be due to them having higher levels of angiotensin II and, consequently, higher levels of ACE2 to degrade it and thus reduce its harmful effects on the lungs. Also supporting the idea of the presence of excess angiotensin II in this process is the fact that both patients who have SARS-CoV-2 infection and patients who have survived SARS-CoV-2 infection have a higher incidence of hypertension, cardiovascular problems, and glucose metabolism disorders.²²

According to this hypothesis, blocking angiotensin II production with ACE inhibitors could be an alternative for decreasing its levels and its inflammatory potential in the lungs and, consequently, decreasing ACE2 expression. This

would render the virus less infectious in the early phases of the disease and in contacts, as it would decrease the receptors available for the SARS-CoV-2 virus to enter cells. Experimental studies have found that ACE2 knockout mice are not infected by these viruses.¹³ It has also been suggested that ACE inhibitors could partly alter the structure of the enzyme due to their similarity to ACE, which would also impede the binding of the virus.⁵

With respect to more severe cases, the data are more contradictory, as it has been reported that the drop in ACE2 activity caused by the virus could increase lung injury, although under these circumstances the possible benefit of ACE2 could be due to the fact that it increases angiotensin II degradation, which would be elevated by a defect in its regulation and an increase in renin activity stimulated by hypoxia. Such conditions, which are seen in 5%–10% of patients with SARS-CoV-2 infection, are characterized by devastating acute inflammation with predominant pulmonary expression (pneumonia, hypoxia, and severe respiratory distress) and are probably tied to different expressions of interferon, patterns of cytokines, and other unknown molecular mechanisms, which would explain the different clinical presentations, independent of patient age.²³

It is interesting to note that there are differences between individuals in terms of the structure of ACE and its accompanying effects. Different studies have shown the phar-

macrogenomic significance of the three variants of endothelial nitric oxide synthases (eNOS) with regard to ACE inhibition responses. Genetic variability in eNOS genes and in the genes that contribute to their activation could affect the ACE inhibitor response. One of these studies focused on patients with hypertension treated with enalapril, an ACE inhibitor.²⁴

The beneficial effects of ACE inhibition in the lungs have been demonstrated in various studies, both experimentally (enalapril was found to exert an anti-inflammatory effect in an animal model of induced pulmonary toxicity,²⁵ and perindopril, another ACE inhibitor, was found to have the same effect on lung impairment secondary to sepsis²⁶) and clinically (through a meta-analysis that found ACE inhibitors to possess a protective effect with respect to pneumonia risk).²⁷

The clinical effect of ACE inhibitors and ARBs in patients with COVID-19 who require hospital admission is being evaluated in a study in progress at King's College Hospital and Princess Royal University Hospital in London.²⁸ Its preliminary results do not find a worse course in patients treated with ACE inhibitors compared to patients not taking these drugs; it is even noted that they seem to follow a more favorable course. Regarding ARBs, it is not yet possible to draw conclusions given the limited number of cases analyzed.

Regardless of other more specific treatment options — antivirals, direct ACE2 blockade, treatment with recombinant ACE2 in an attempt to saturate the capacity for binding of the virus to the same, vaccines, and others^{29,30} — the option proposed should be considered because it is a well-known, accessible, and safe treatment, if administered with proper management and monitoring, which could aid in reducing the spread and effects of the infection.

In an initial phase, it would be necessary, as other authors have remarked,^{13,18} to analyze as soon as possible the epidemiological data available for infected patients, with respect to their course and history of taking antihypertensive drugs; at the same time, it would be appropriate to propose randomized prospective studies in initial infections in which one of the arms includes not only the treatment considered most suitable for each case but also an ACE inhibitor, with strict clinical management of these patients, in line with those already started by other researchers.

It is necessary to continue conducting research aimed at improving knowledge of the correlation between angiotensin II levels and ACE2 activity in different tissues — lung, heart, and kidney tissues — since it seems that the degree of activity of the components of the RAS may vary by organ and in accordance with plasma levels. In addition, it must be clarified whether the possible beneficial effect reported with higher ACE2 levels is due to greater degradation of angiotensin II and increased angiotensin 1–7 or to an action through other metabolic pathways.

We also believe that it is very important to have, as soon as possible, results from regulated and systematized studies on the effects of blockade of angiotensin II and other components of the RAS in SARS-CoV-2 infection, since the lack of scientific evidence in this regard is resulting in a proliferation of scientific literature with highly conflicting opinions on the possible effects of the drugs that interfere with this system, based only on experimental studies with many limitations, such as some of those mentioned, and on subjective interpretations.^{31,32}

Indeed, there have even been formal — and, we believe, hasty — proposals of actions contrary to the positioning of scientific associations and the European Medicines Agency on the use of these medicines in patients with COVID-19.³³

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgment

We would like to thank Dr. Sara Lamas-Alvarez for her useful suggestions and contributions in improving and clarifying the content of the manuscript.

REFERENCES

1. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *Int J Pept.* 2012;2012:256294, <http://dx.doi.org/10.1155/2012/256294>.
2. Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. *Adv Chronic Kidney Dis.* 2011;18:28–41, <http://dx.doi.org/10.1053/j.ackd.2010.10.003>.
3. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J Virol.* 2020;94, <http://dx.doi.org/10.1128/JVI.00127-20>, e00127-20.
4. Yan R, Zhang Y, Li Y, Xia L, Gui Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science.* 2020;367:1444–8, <http://dx.doi.org/10.1126/science.abb2762>.
5. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. *Biochem Biophys Res Commun.* 2020;525:135–40, <http://dx.doi.org/10.1016/j.bbrc.2020.02.071>.
6. Soler MJ, Lloverasa J, Batlle D. Enzima conversiva de la angiotensina 2 y su papel emergente en la regulación del sistema renina-angiotensina. *Med Clin (Barc).* 2008;131:230–6, <http://dx.doi.org/10.1157/13124619>.
7. Nieto J, Robles NR, Liébana A. El sistema renina-angiotensina: ¿hasta dónde se expande?, ¿es posible bloquearlo? *Nefrología Sup Ext.* 2011;2:48–56, <http://dx.doi.org/10.3265/NefrologiaSuplementoExtraordinario.pre2011.Jul.11073>.
8. Santeliz-Contra H, Romano-Estrada L, González-Chávez A, Hernández-Hernández H. El sistema renina-angiotensina-aldosterona y su papel funcional más allá del control de la presión arterial. *Rev Mex Cardiol.* 2008;19:21–9.
9. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem.* 2002;277:14838–43, <http://dx.doi.org/10.1074/jbc.M200581200>.
10. Ramchand J, Patel SK, Piyush M, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. *PLoS One.* 2018;13:e0198144, <http://dx.doi.org/10.1371/journal.pone.0198144>.

11. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, et al. Targeting the degradation of angiotensin ii with recombinant ACE2: prevention of angiotensin II-dependent hypertension. *Hypertension*. 2010;55:90–8, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.138420>.
12. Danilczyk U, Josef M, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. *Circ Res*. 2006;98:463–71, <http://dx.doi.org/10.1161/01.RES.0000205761.22353.5f>.
13. Imai Y, Kuba K, Penninger JM. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Cell Mol Life Sci*. 2007;64:2006–12, <http://dx.doi.org/10.1007/s00018-007-6228-6>.
14. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res*. 2020:1–4, <http://dx.doi.org/10.1002/ddr.21656>.
15. Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. *Chin J Tuberc Respr Dis*. 2020;43:219–22, <http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.03.016>.
16. Phadke M, Saunik S. Use of angiotensin receptor blockers such as Telmisartan, Losartan in nCoV Wuhan CoronaVirus infections—Novel mode of treatment. Rapid response to: The emerging novel coronavirus outbreak. *BMJ*. 2020;368:m406, <http://dx.doi.org/10.1136/bmj.m406>.
17. Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. *Sci Rep*. 2014;4:7027, <http://dx.doi.org/10.1038/srep07027>.
18. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. *Circulation*. 2005;111:2605–10, <http://dx.doi.org/10.1161/CIRCULATIONAHA.104.510461>.
19. Sommerstein R, Gräni C. ACE inhibitors as a potential risk factor for fatal Covid-19. Rapid response to: Preventing a covid-19 pandemic. *BMJ*. 2020;368:m810, <http://dx.doi.org/10.1136/bmj.m810>.
20. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM, et al. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. *Europace*. 2017;19:1280–7, <http://dx.doi.org/10.1093/europace/euw246>.
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054–62, [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3).
22. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17:259–60, <http://dx.doi.org/10.1038/s41569-020-0360-5>.
23. Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents*. 2020;34:1, <http://dx.doi.org/10.23812/CONTI-E>.
24. Silva PS, Fontana V, Luizon MR, Racchini R, Silva WA Jr, Biagi C, et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. *Eur J Clin Pharmacol*. 2013;69:167–77, <http://dx.doi.org/10.1007/s00228-012-1326-2>.
25. Wang SL, Yuan B, Dan QQ, Yang XY, Meng BL, Zhang YH. Effects of enalapril on IL-1beta, IL-6 expression in rat lung exposure to acrolein. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2010;41, 1003–100, 1038.
26. Kostakoglu U, Topcu A, Atak M, Tumkaya L, Mercantepe T, Uydu HA. The protective effects of angiotensin-converting enzyme inhibitor against cecal ligation and puncture-induced sepsis via oxidative stress and inflammation. *Life Sci*. 2020;241:117051, <http://dx.doi.org/10.1016/j.lfs.2019.117051>.
27. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. *BMJ*. 2012;345:e4260, <http://dx.doi.org/10.1136/bmj.e4260>.
28. Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. *medRxiv*. 2020, <http://dx.doi.org/10.1101/2020.04.07.20056788>.
29. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. *F1000Res*. 2020;9:72, <http://dx.doi.org/10.12688/f1000research.22211.2>.
30. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. 2020;46:586–90, <http://dx.doi.org/10.1007/s00134-020-05985-9>.
31. Mourad JJ, Levy BI. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. *Nat Rev Cardiol*. 2020;17:313, <http://dx.doi.org/10.1038/s41569-020-0368-x>.
32. Zheng YY, Ma YT, Zhang JY, Xie X. Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'. *Nat Rev Cardiol*. 2020;17:313–4, <http://dx.doi.org/10.1038/s41569-020-0369-9>.
33. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. *BMJ*. 2020;369:m1313, <http://dx.doi.org/10.1136/bmj.m1313>.